×
About 875 results

ALLMedicine™ Anaplastic Thyroid Carcinoma Center

Research & Reviews  323 results

Anaplastic thyroid carcinoma: advances in molecular profiling and targeted therapy.
https://doi.org/10.1097/CCO.0000000000000918
Current Opinion in Oncology; Jungels C, Pita JM et. al.

Nov 19th, 2022 - Anaplastic thyroid carcinomas (ATCs) are rare cancers with a globally very poor prognosis, because of their immensely aggressive behaviour, resulting in predominantly advanced stage of disease at diagnosis. Response to available therapies is still...

EIF1AX mutation in thyroid tumors: a retrospective analysis of cytology, histopathology...
https://doi.org/10.1186/s40463-022-00594-6
Journal of Otolaryngology - Head & Neck Surgery = Le Jour... Elsherbini N, Kim DH et. al.

Nov 13th, 2022 - The EIF1AX mutation has been identified in various benign and malignant thyroid lesions, with a higher prevalence in poorly differentiated thyroid carcinoma (PDTC) and anaplastic thyroid carcinoma, especially when combined with RAS or TP53 mutatio...

B3 thymoma mimicking poorly differentiated thyroid carcinoma: Diagnostic pitfalls of an...
https://doi.org/10.1002/dc.25075
Diagnostic Cytopathology; Bartels A, Bykowski J et. al.

Nov 11th, 2022 - B3 thymoma is a rare malignant type of thymic epithelial neoplasm found in the anterior mediastinum. Diagnosis of thymoma from fine needle aspiration (FNA) can be challenging due to the infrequency of sampling and its morphologic overlap with othe...

Pathologic complete response after neoadjuvant v-Raf murine sarcoma viral oncogene homo...
https://doi.org/10.1507/endocrj.EJ22-0366
Endocrine Journal; Song Y, Bai Y et. al.

Nov 10th, 2022 - Anaplastic thyroid carcinoma (ATC) is a highly malignant tumor with invasive nature. Most patients present with locally advanced and/or distant metastatic diseases that are difficult to treat. We report a case of a previously inoperable patient wi...

High-Resolution Ultrasonography for the Analysis of Orthotopic ATC Tumors in a Genetica...
https://doi.org/10.3791/64615
Journal of Visualized Experiments : JoVE; He Y, Luo Y et. al.

Nov 1st, 2022 - Anaplastic thyroid carcinoma (ATC) is associated with a poor prognosis and short median survival time, but no effective treatment improves the outcomes significantly. Genetically engineered murine models that mimic ATC's progression may help resea...

see more →

Guidelines  3 results

The revised clinical practice guidelines on the management of thyroid tumors by the Jap...
https://doi.org/10.1507/endocrj.EJ20-0025
Endocrine Journal; Ito Y, Onoda N et. al.

Apr 10th, 2020 - The Japan Associations of Endocrine Surgeons has developed the revised version of the Clinical Practice Guidelines for Thyroid Tumors. This article describes the guidelines translated into English for the 35 clinical questions relevant to the ther...

NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018.
https://doi.org/10.6004/jnccn.2018.0089
Journal of the National Comprehensive Cancer Network : JN... Haddad RI, Nasr C et. al.

Dec 14th, 2018 - The NCCN Guidelines for Thyroid Carcinoma provide recommendations for the management of different types of thyroid carcinoma, including papillary, follicular, Hürthle cell, medullary, and anaplastic carcinomas. These NCCN Guidelines Insights summa...

Anaplastic Thyroid Carcinoma, Version 2.2015.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986600
Journal of the National Comprehensive Cancer Network : JN... Haddad RI, Lydiatt WM et. al.

Sep 12th, 2015 - This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Thyroid Carcinoma focuses on anaplastic carcinoma because substantial changes were made to the systemic therapy recommendations for the 2015 update. Dosage...

see more →

Clinicaltrials.gov  5 results

A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT04592484

Sep 28th, 2022 - This is a first-in-human, Phase 1/2 open-label, multicenter, dose escalation, safety, pharmacodynamic, and PK study of CDK-002 in subjects with advanced/metastatic, recurrent, injectable solid tumors, whose disease has progressed despite receiving...

Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer
https://clinicaltrials.gov/ct2/show/NCT03181100

Jul 15th, 2022 - PRIMARY OBJECTIVE: I. To determine if targeted therapy + atezolizumab (cohorts 1-3) will lead to improved overall survival (OS) in patients with anaplastic thyroid carcinoma (ATC). SECONDARY OBJECTIVES: I. To evaluate the safety and efficacy (Resp...

Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients
https://clinicaltrials.gov/ct2/show/NCT02114658

Aug 3rd, 2017 - The objectives of this study are to evaluate safety, efficacy and pharmacokinetics of sorafenib for the treatment of Japanese patients with anaplastic thyroid carcinoma (ATC) or locally advanced or metastatic medullary thyroid carcinoma (MTC).

Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer
https://clinicaltrials.gov/ct2/show/NCT00507429

Jun 9th, 2014 - Anaplastic thyroid carcinoma (ATC) is a high-grade neoplasm, characterized by an aggressive clinical course with brief survival, and refractoriness to currently available local and systemic modalities of treatment. There is no standard therapy for...

Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma
https://clinicaltrials.gov/ct2/show/NCT00115739

Apr 21st, 2014 - Anaplastic thyroid carcinomas (ATC) are high grade neoplasms, which account for approximately 2% to 5% of primary malignant thyroid tumors but more than 50% of thyroid cancer deaths. Because therapies for anaplastic thyroid carcinoma are very limi...

see more →

News  19 results

Tumor Profiling Studies Illuminate Nuances Across Malignancies
https://www.onclive.com/view/tumor-profiling-studies-illuminate-nuances-across-malignancies

Nov 21st, 2022 - Molecular and immune landscapes for solid tumors are constantly evolving as precision medicine techniques become more sensitive and next-generation sequencing methods (NGS) are taken up in clinical practice. Posters presented at the European Soc...

Lenvatinib/Pembrolizumab Combo Proves Safe, Effective for Metastasized Anaplastic and Poorly Differentiated Thyroid Carcinoma
https://www.onclive.com/view/lenvatinib-pembrolizumab-combo-proves-safe-effective-for-metastasized-anaplastic-and-poorly-differentiated-thyroid-carcinoma

Sep 13th, 2022 - The combination of lenvatinib (Lenvima) and pembrolizumab (Keytruda) was found to induce high response rates, including long-lasting remissions, and have acceptable safety in patients with metastasized anaplastic thyroid carcinoma (ATC) and poorly...

Running, a Lot of Discipline, and a Little Bit of Jazz: Walter J. Curran Jr Is a Giant of Cancer Care in Radiation Oncology
https://www.onclive.com/view/running-a-lot-of-discipline-and-a-little-bit-of-jazz-walter-j-curran-jr-is-a-giant-of-cancer-care-in-radiation-oncology

Apr 6th, 2022 - Walter J. Curran Jr, MD, started a new job this year working for an Australia-based oncology services provider, so it’s no surprise that he spent the summer with his mind and his device screens tethered to the other side of the world. Then again,...

Molecular Testing Enhances Decision-Making Process in Thyroid Cancer of Indeterminate Malignancy
https://www.onclive.com/view/molecular-testing-enhances-decisionmaking-process-in-thyroid-cancer-of-indeterminate-malignancy

Jan 3rd, 2022 - Andrew Turk, MD In thyroid cancer, molecular diagnostic tests enable oncologists to evaluate thyroid nodules with atypical, suspicious, or indeterminate fine-needle aspiration (FNA) cytology to determine the best course of treatment based on cyto...

Next-Generation BRAF Inhibitor Plus Cobicistat Elicits Encouraging Activity in BRAF+ Refractory Solid Tumors
https://www.onclive.com/view/next-generation-braf-inhibitor-cobicistat-elicits-encouraging-activity-in-braf-refractory-solid-tumors

Oct 6th, 2021 - PLX8394, a next-generation BRAF inhibitor, in combination with cobicistat (Tybost) was found to demonstrate encouraging clinical activity with an acceptable safety profile in patients with BRAF-mutated, refractory solid tumors, according to result...

see more →